What Lilly actually does

Eli Lilly and Company was founded in 1876 in Indianapolis by Eli Lilly, a pharmaceutical chemist and Civil War veteran. It is now a global drug maker with products sold in roughly 125 countries and counts among the largest pharmaceutical companies by value.

Lilly is best known today for medicines that treat diabetes and obesity, but it also sells treatments for cancer, immune conditions, neurological diseases and other areas. It developed some of the first commercial insulin products in the 1920s.

How the business makes money

Lilly earns money by selling prescription drugs that are protected by patents. While a patent lasts, the company can charge prices that reflect the value of a new treatment. When the patent ends, cheaper generics arrive and sales usually fall sharply.

That makes the pipeline the key to the whole business: new drugs have to be developed and approved before older ones lose protection. In recent years the diabetes and weight-loss medicines tirzepatide (sold as Mounjaro and Zepbound) have driven much of the company’s growth.

The dividend story

Lilly has paid dividends for well over a century and has raised them regularly in recent years. The yield is low, because the share price has climbed so strongly, but the payout has grown alongside earnings.

It is a good example of a company where the dividend growth rate is more interesting than the starting yield. It is also a reminder to check the payout ratio, since a drug company’s earnings can change quickly when a major product gains or loses momentum.

What to keep an eye on

  • Concentration. A few medicines account for a large share of growth.
  • Pricing pressure. Governments and insurers push to lower drug prices.
  • Competition. Rival makers are racing in the obesity-drug market.
  • Manufacturing capacity. Meeting demand for new medicines needs large investment.
  • Patent expiry. Every drug eventually faces generic competition.

Quick take

Lilly combines a very long dividend record with strong growth in some of the most in-demand medicines. The yield is small, but the growth story is the reason many investors hold it.